EGFR and colonic neoplasm: Cetuximab (Erbitux) antibody is conjugated on PNIPAAm to allow the active targeting (Figs 1b and 4b−d) of epidermal growth factor receptors that are overexpressed in colon cancer (HT-29) cells.